March 29, 2018Open Access

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected cohort of patients (20%) and is associated with significantly longer median overall survival.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Gemenetzis et al. (Thu,) studied this question.

synapsesocial.com/papers/69d6f5ccf174babf6cab3c2b https://doi.org/https://doi.org/10.1097/sla.0000000000002753

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer statistics, 20172017 · 14,972 citations
2Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis2011 · 87 citations
3Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX2017 · 325 citations
4Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma2017 · 110 citations
5Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer2016 · 143 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo